

# Wenzhe Fan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5116444/publications.pdf>

Version: 2024-02-01

48  
papers

726  
citations

687363

13  
h-index

642732

23  
g-index

51  
all docs

51  
docs citations

51  
times ranked

951  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Survival and Metastasis for Recurrent Hepatocellular Carcinoma after Transarterial Chemoembolization. PLoS ONE, 2015, 10, e0119312.	2.5	77
2	High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39 <sup>+</sup> CD8 <sup>+</sup> T cells. Gut, 2021, 70, 1965-1977.	12.1	72
3	Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis. Oncologist, 2015, 20, 1417-1424.	3.7	68
4	Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience. Oncologist, 2016, 21, 1442-1449.	3.7	50
5	Comparison between microwave ablation and lobectomy for stage I non-small cell lung cancer: a propensity score analysis. International Journal of Hyperthermia, 2018, 34, 1329-1336.	2.5	36
6	Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. Clinical Therapeutics, 2019, 41, 1463-1476.	2.5	36
7	&lt;p&gt;Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study&lt;/p&gt;. OncoTargets and Therapy, 2020, Volume 13, 12683-12693.	2.0	26
8	Comparison of intraluminal radiofrequency ablation and stents vs. stents alone in the management of malignant biliary obstruction. International Journal of Hyperthermia, 2017, 33, 1-9.	2.5	24
9	Percutaneous intraductal radiofrequency ablation in the management of unresectable Bismuth types III and IV hilar cholangiocarcinoma. Oncotarget, 2016, 7, 53911-53920.	1.8	23
10	Doxorubicin-Loaded UiO-66/Bi <sub>2</sub> S <sub>3</sub> Nanocomposite-Enhanced Synergistic Transarterial Chemoembolization and Photothermal Therapy against Hepatocellular Carcinoma. ACS Applied Materials & Interfaces, 2022, 14, 7579-7591.	8.0	18
11	Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study. Cancer Control, 2019, 26, 107327481987221.	1.8	17
12	Percutaneous computed tomography-guided cryoablation for recurrent retroperitoneal soft tissue sarcoma: a study of safety and efficacy. Oncotarget, 0, 7, 42639-42649.	1.8	17
13	Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: A phase 3, multicenter, randomized controlled trial.. Journal of Clinical Oncology, 2022, 40, 380-380.	1.6	17
14	Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS. European Radiology, 2021, 31, 8291-8301.	4.5	15
15	Decreased WWOX expression promotes angiogenesis in osteosarcoma. Oncotarget, 2017, 8, 60917-60932.	1.8	14
16	Impact of type 2 diabetes mellitus on short-term and long-term outcomes of patients with esophageal squamous cell cancer undergoing resection: a propensity score analysis. Cancer Communications, 2018, 38, 1-9.	9.2	14
17	&lt;p&gt;Dynamic Changes in the Neutrophil-to-Lymphocyte Ratio Predict the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization&lt;/p&gt;. Cancer Management and Research, 2020, Volume 12, 3433-3444.	1.9	13
18	The safety and efficacy of percutaneous intraductal radiofrequency ablation in unresectable malignant biliary obstruction: A single-institution experience. BMC Cancer, 2017, 17, 288.	2.6	12

#	ARTICLE	IF	CITATIONS
19	Large hepatocellular carcinomas: treatment with transarterial chemoembolization alone or in combination with percutaneous cryoablation. <i>International Journal of Hyperthermia</i> , 2018, 35, 239-245.	2.5	10
20	Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 487-494.	2.5	10
21	Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. <i>Cancer Management and Research</i> , 2021, Volume 13, 4013-4029.	1.9	10
22	Alpha-fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization. <i>Abdominal Radiology</i> , 2019, 44, 3304-3311.	2.1	9
23	Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1625-1633.	2.5	9
24	Efficacy of intra-arterial chemotherapy combined with intravesical chemotherapy in T1G3 bladder cancer when compared with intravesical chemotherapy alone after bladder-sparing surgery: a retrospective study. <i>World Journal of Urology</i> , 2019, 37, 823-829.	2.2	9
25	A meta-analysis of the efficacy and safety of iodine [131I] metuximab infusion combined with TACE for treatment of hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, 451-459.	1.5	9
26	Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093742.	3.2	9
27	Prognostic Value of TP53 Mutation for Transcatheter Arterial Chemoembolization Failure/Refractoriness in HBV-Related Advanced Hepatocellular Carcinoma. <i>Cancer Research and Treatment</i> , 2020, 52, 925-937.	3.0	9
28	Feasibility and Efficacy of Microwave Ablation Combined with Iodine-125 Seed Implantation in Local Control of Recurrent Retroperitoneal Liposarcomas: Initial Clinical Experience. <i>Oncologist</i> , 2017, 22, 1500-1505.	3.7	8
29	A novel mechanism of the M1-M2 methionine adenosyltransferase switch-mediated hepatocellular carcinoma metastasis. <i>Molecular Carcinogenesis</i> , 2018, 57, 1201-1212.	2.7	8
30	Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. <i>Oncologist</i> , 2019, 24, e1489-e1495.	3.7	8
31	Unresectable Hepatocellular Carcinoma: Transcatheter Arterial Chemoembolization Combined With Microwave Ablation vs. Combined With Cryoablation. <i>Frontiers in Oncology</i> , 2020, 10, 1285.	2.8	8
32	Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response. <i>Oncotarget</i> , 2015, 6, 24550-24559.	1.8	7
33	The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization. <i>European Radiology</i> , 2021, 31, 232-243.	4.5	7
34	Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin. <i>Oncotarget</i> , 2017, 8, 79165-79174.	1.8	6
35	Silencing SAPCD2 Represses Proliferation and Lung Metastasis of Fibrosarcoma by Activating Hippo Signaling Pathway. <i>Frontiers in Oncology</i> , 2020, 10, 574383.	2.8	6
36	A 10-Gene Signature Identified by Machine Learning for Predicting the Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	1.3	6

#	ARTICLE	IF	CITATIONS
37	The role of associating liver partition and portal vein ligation for staged hepatectomy in unresectable hepatitis B virus-related hepatocellular carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1402-1402.	1.7	5
38	Interaction between hepatitis B virus infection and the efficacy of camrelizumab in combination with apatinib therapy in patients with hepatocellular carcinoma: a multicenter retrospective cohort study. <i>Annals of Translational Medicine</i> , 2021, 9, 1412-1412.	1.7	5
39	Diffuse Recurrence of Hepatocellular Carcinoma After Liver Resection: Transarterial Chemoembolization (TACE) Combined With Sorafenib Versus TACE Monotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 574668.	2.8	5
40	Clinical Significance of Peripheral Blood Lymphocyte Subtypes and Cytokines in Patients with Hepatocellular Carcinoma Treated with TACE. <i>Cancer Management and Research</i> , 2022, Volume 14, 451-464.	1.9	4
41	Prolonged progression-free survival achieved by octreotide plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden. <i>Cancer Medicine</i> , 2022, 11, 2588-2600.	2.8	4
42	Time to untreatable progression is an appropriate surrogate endpoint for overall survival in patients with hepatocellular carcinoma after transarterial chemoembolization. <i>Journal of Cancer Research and Therapeutics</i> , 2020, 16, 301-308.	0.9	3
43	Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization. <i>European Radiology</i> , 2022, 32, 5799-5810.	4.5	3
44	Advanced hepatocellular carcinoma treated by transcatheter arterial chemoembolization with drug-eluting beads plus lenvatinib versus sorafenib, a propensity score matching retrospective study.. <i>American Journal of Cancer Research</i> , 2021, 11, 6107-6118.	1.4	0
45	Non-Apoptotic Programmed Cell Death-Related Gene Signature Correlates With Stemness and Immune Status and Predicts the Responsiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 844013.	3.7	0
46	<i>TP53</i> pathogenic variants with low allele fraction in germline genetic testing.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10600-10600.	1.6	0
47	The frequency of rare <i>ALK</i> fusions and their clinical significance in NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21012-e21012.	1.6	0
48	TACE with idarubicin-eluting beads compared with TACE with epirubicin-eluting beads in BCLC B-stage HCC: Interim results of a randomized, double-blind, parallel-controlled, phase IV multicenter study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4068-4068.	1.6	0